Other

USA

My cart

In the shopping cart is not goods, to choose and buy!

Product Name
Size
Quantity
Amount

All Selected items : 0 pieces Total : CHECK OUT()

location： Home > Products > Signaling Pathways > Apoptosis > p53

JNJ-26854165 (Serdemetan)

Price：

Market Price：

This product is for research use only, not for human use. We do not sell to patients.

Number： - + Pieces（InventoryPieces）

InvivoChem Cat #: V0013

CAS #: 881202-45-5Purity ≥98%

Description: Serdemetan (formerly JNJ26854165; JNJ-26854165; JNJ 26854165), originally developed as an activator of p53, is now considered to be a novel, potent and orally bioactive antagonist of Human Double Minute-2 (HDM-2) ubiquitin ligase with antitumor activities. It also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53.

Reference: Pediatr Blood Cancer. 2012 Aug;59(2):329-32.

Customer Validation

Top Publications Citing Invivochem Products

Bulletin Board Product Catalog 2023

Bulletin Board

详情页公告 Guide to Product Handling

Publications Citing InvivoChem Products

Physicochemical and Storage Information
Protocol
Quality Control Documentation
Related Biological Data
Customer Review

Molecular Weight (MW)	328.41
Formula	C21H20N4
CAS No.	881202-45-5
Storage	-20℃ for 3 years in powder form
Storage	-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: 66 mg/mL (200.96 mM)
	Water:<1 mg/mL (slightly soluble or insoluble)
	Ethanol: 2 mg/mL (6.08 mM)
Solubility (In vivo)	1% DMSO+30% polyethylene glycol+1% Tween 80: 30 mg/mL
Synonyms	JNJ26854165; JNJ-26854165; JNJ 26854165

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
- Mass
- Concentration
- Volume
- Molecular Weight *
- =
- ×
- ×
The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂
- Concentration _(start)
- ×
- Volume _(start)
- =
- Concentration _(final)
- ×
- Volume _(final)
- ×
- =
- ×
- C1
- V1
- C2
- V2

General	JNJ 26854165 leads to significant differences in EFS distribution in 17 of the 36 (47%) evaluable solid tumor xenografts and in 5 of 7 (71%) of the evaluable ALL xenografts using a dose of 20 mg/kg administered via oral gavage daily for 5 days, repeated for 6 weeks
Animal model	CB17SC scid female mice.
Formulation	Dissolved in DMSO and then diluted in water.
Dosages	20 mg/kg
Administration	Oral gavage
Reference	[1] Smith MA, et al. Pediatr Blood Cancer, 2012, 59(2), 329-332.